250mg

Revosirox

Revosirox 250mg Tablet

Deferasirox

KAIZEN PHARMACEUTICALS PVT LTD.

Drug Identity

Active Ingredient
Deferasirox
Drug Class
All Other Therapeutic Products, Antidotes
ATC Code
V03AC03
Status
Essential Medicine

What is Revosirox?

Uses
Monjuvi is used to treat diffuse large B-cell lymphoma (DLBCL ) in combination with lenalidomide that is relapsed or refractory (r/r), or...

How to Take It

Dosage information not available for this product.

Safety Alerts

Before you receive Monjuvi, tell your healthcare provider about all of your medical conditions, including if you: have an active infection or have had one recently are pregnant or plan to become pregnant are breastfeeding or plan to breastfeed

Important Warnings

Pregnancy & lactation, elderly, history of liver cirrhosis, not recommended in conditions which may reduce life expectancy such as high-risk myelodysplastic syndromes, platelet count less than 50x109/litre, risk of GI ulceration and haemorrhage, unexplained cytopenia
discontinue treatment
Monitor serum transaminase monthly: Renal & hepatic impairment
Interrupt therapy if severe rash develops
Perform ophthalmological, audiological testing annually
Not to be combined with other Fe chelator therapy
Not recommended in rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption

Side Effects

Abdominal distension and painheadacheconstipationdiarrhoeadyspepsiaGI haemorrhage and ulcerationnauseavomitingproteinuriapruritusraised serum creatinineraised transaminasesrashanxietycataract

Drug Interactions

Aluminium containing antacids.

Pregnancy & Lactation

Pregnancy
Avoid unless essential
Lactation
Avoid

Price Intelligence

Rs 8,054.7
DRAP approved maximum price · per pack of 30 · approved 22 Jul, 2026
No retail price observed for this pack. Retailers may not exceed the approved maximum.
Prices across sources
DRAPper pack of 30Rs 8,054.7

Should you consider an alternative?

Other options containing Deferasirox, and what they are not.

For pharma professionalsCompany, market and opportunity intelligence

Company

Prices as of 30 July 2026 · DRAP ceiling as of 30 July 2026 · schema v3-SKU

For medicine intelligence and professional reference only. Not medical advice.